Fact CheckerSign in

NCT07243639Recruiting

Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis

Source: ClinicalTrials.gov · Last updated 21 Jul 2026

Brief summary (registry, in English)

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
30 (estimated)
First submitted
14 Nov 2025
Start date
1 Oct 2025
Primary completion date
30 Sept 2027
Lead sponsor
Showa Inan General Hospital
NCT number
NCT07243639

What you commit to

  • Study type: Interventional
  • Planned participants: 30
  • From 1 Oct 2025 to the primary completion date, 30 Sept 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease

Who the study is looking for

  • Patients with active ulcerative colitis

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Showa Inan General Hospital
Coordinator of this site? Confirm its status		KomaganeJapanRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.